Sign in
EG

Easterly Government Properties, Inc. (DEA)·Q2 2025 Earnings Summary

Executive Summary

  • Q2 2025 delivered revenue and EBITDA upside with Core FFO per share edging to $0.74, while GAAP EPS of $0.09 trailed consensus; full‑year Core FFO guidance was maintained at $2.98–$3.03 on a fully diluted basis, signaling steady trajectory .
  • Top‑line strength reflected portfolio growth and accretive acquisitions (DC – Capitol Plaza; DHS – Burlington), while higher interest expense weighed on GAAP EPS year over year (interest expense +$3.8M YoY) .
  • Balance sheet/liquidity remained adequate for selective growth (cash interest coverage 3.0x; revolver availability $122.3M; expected ~$115M FDA Atlanta lump‑sum later in 2025), supporting continued development and state/local diversification .
  • Management emphasized mission‑critical tenancy, renewal execution (soft‑term exposure down to 4.7%), and disciplined capital allocation as catalysts, with the maintained guide and visible cash inflows likely anchoring near‑term sentiment .

What Went Well and What Went Wrong

  • What Went Well

    • Revenue, EBITDA and Core FFO per share improved sequentially; Core FFO/share of $0.74 vs $0.73 in Q1; EBITDA rose to $54.3M from $51.0M, aided by acquisitions and stable operations .
    • Strategic growth: closed DHS – Burlington (Level IV, 10‑year non‑cancelable), advanced JUD – Medford courthouse, and secured a 25‑year FDLE Fort Myers crime lab (groundbreaking held July 31) .
    • Renewal progress and portfolio durability: soft‑term exposure declined to 4.7%; management sees no breaks in tenancy and highlighted a recent USFS renewal at Albuquerque as a positive signal .

  • What Went Wrong

    • GAAP EPS declined YoY to $0.09 from $0.11, primarily due to higher interest expense ($19.0M vs $15.2M YoY) despite stronger revenues .
    • Leverage remains elevated by REIT standards (Adjusted Net Debt to annualized pro forma EBITDA 7.2x), maintaining a reliance on disciplined capital allocation and selective dealmaking .
    • Dividend was previously reset (April) and held at $0.45 this quarter; while aligning payout with earnings capacity, it underscores near‑term capital cost constraints as a headwind to external growth velocity .

Financial Results

MetricQ4 2024Q1 2025Q2 2025
Total Revenues ($M)$78.25 $78.68 $84.23
Net Income ($M)$5.73 $3.28 $4.25
Diluted EPS ($)$0.05 $0.07 $0.09
FFO per Share ($)$0.29 $0.71 $0.74
Core FFO per Share ($)$0.29 $0.73 $0.74
EBITDA ($M)$49.87 $50.96 $54.28
Cash Available for Distribution ($M)$25.09 $31.15 $29.30

Estimates vs Actuals – Q2 2025

MetricConsensusActualSurprise
Revenue ($M)$82.66*$84.23 +$1.57 (+1.9%)*
EBITDA ($M)$51.34*$54.28 +$2.94 (+5.7%)*
GAAP Diluted EPS ($)$0.14*$0.09 −$0.05 (−35.7%)*
  • Note: Consensus from S&P Global; values marked with * are retrieved from S&P Global.

KPIs and Balance Sheet (as of Q2 2025)

KPIValue
Properties (incl. JV)102
Leased Square Feet~10.1M
WALT (years)9.6
Net Debt / Total Enterprise Value62.2%
Adjusted Net Debt / Annualized Pro Forma EBITDA7.2x
Cash Interest Coverage3.0x
Cash Fixed Charge Coverage2.8x
Cash & Equivalents$5.79M
Revolver Availability$122.33M
Quarterly Dividend$0.45 per share (payable Aug 25)

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Core FFO per Share (fully diluted)FY 2025$2.98 – $3.03 $2.98 – $3.03 Maintained
Net Income per Share (fully diluted)FY 2025$0.48 – $0.53 $0.48 – $0.53 Maintained
Wholly Owned Acquisitions AssumptionFY 2025~$140M ~$140M Maintained
Development Investment (gross)FY 2025$25 – $75M $25 – $75M Maintained
DividendQ2 2025$0.45 (post reset) $0.45 Maintained

Earnings Call Themes & Trends

TopicPrevious Mentions (Q4’24 and Q1’25)Current Period (Q2’25)Trend
DOGE/government efficiency, mission‑critical focusEmphasized shift towards leased, modern facilities; mission‑critical assets resilient Continued focus on mission‑critical renewals; “no breaks in tenancy”; portfolio stability Stable to improving
Renewal execution/soft‑term exposureWALT ~10 yrs; process and rent/TI timing explained Soft‑term down to 4.7%; cited USFS Albuquerque renewal Improving
Capital allocation/dividend resetReset payout and 1‑for‑2.5 reverse split to enhance flexibility Dividend maintained; focus on selective, accretive growth Steady
Cost of capital and return hurdlesTarget 50–100 bps spread; costs higher‑for‑longer acknowledged Development “in the 10s” cap rate; ~150 bps spread to cost of capital Steady discipline
Pipeline & state/local diversificationPipeline robust; expanding TAM to state/local and adjacent Pipeline “$1B–$1.5B” viewed; ongoing state/local wins (FDLE Fort Myers) Expanding
Liquidity/cash inflowsExtended 2016 TL; revolver in place $122M revolver availability; ~$115M expected FDA Atlanta lump sum in 2025 Positive visibility

Management Commentary

  • CEO: “Our portfolio is stronger, and renewal efforts are producing tangible outcomes.”
  • CFO: “We exceeded consensus expectations for the quarter and remain firmly on track to achieve our full‑year core FFO per share guidance...”
  • On development/economics: “We seek to create about 150 basis point spread to our cost of capital... developed in the 10s on a cap rate basis.”

Q&A Highlights

  • Returns and hurdle rates: Development targeted at ~150 bps over cost of capital; current developments “in the 10s” cap rate range .
  • Pipeline and mix: Pipeline cited at ~$1–$1.5B; mix spans federal (GSA), state/local and government‑adjacent opportunities .
  • Leverage and financing: Long‑term leverage target 6.5x–7.5x; revolver availability ~$122M; expected ~$115M lump‑sum from FDA Atlanta enhances liquidity later in 2025 .
  • Renewals/soft‑term: Soft‑term exposure declined to 4.7%; management not seeing tenancy breaks; expects remaining 2025 rolls to resolve on government timelines .

Estimates Context

  • Q2 2025 results vs S&P Global consensus: Revenue beat (actual $84.23M vs $82.66M*), EBITDA beat (actual $54.28M vs $51.34M*), GAAP EPS miss ($0.09 vs $0.14*). The EPS shortfall reflects higher interest expense YoY despite revenue growth .
  • Forward consensus embeds steady revenue growth; full‑year 2025 Core FFO guidance maintained by the company indicates limited need for estimate cuts near term, but mix shift (debt costs vs accretion) may keep GAAP EPS estimates conservative relative to Core FFO.
  • Values marked with * are retrieved from S&P Global.

Key Takeaways for Investors

  • Core engine steady: Revenue/EBITDA upside and stable Core FFO/share ($0.74) underpin maintained FY guide ($2.98–$3.03), despite GAAP EPS variability from interest expense .
  • Visible cash catalysts: ~$115M FDA Atlanta lump‑sum expected in 2025 plus $122M+ revolver capacity support selective, accretive growth and internal funding of development .
  • Growth vectors intact: Recent closes (DC – Capitol Plaza; DHS – Burlington) and the FDLE Fort Myers lab (25‑year lease) extend duration, diversify beyond federal, and add mission‑critical tenancy .
  • Risk monitor: Elevated leverage (Adj. Net Debt/EBITDA 7.2x) and a higher cost of capital require discipline on spreads (≥150 bps) and timing of external growth .
  • Renewal execution remains a differentiator: Soft‑term exposure down to 4.7% with no observed tenancy breaks; progress on 2025/2026 rolls should help de‑risk the earnings path .
  • Trading setup: Near‑term narrative hinges on sustained guide, execution on announced projects, and realization of FDA cash inflow; further state/local wins and development milestones are potential upside catalysts .

References: Company 8‑K and press releases for Q2 2025 results, guidance, and supplemental data ; Q2 2025 conference call transcript ; Q1 2025 results and call for trend/guidance context ; Q4 2024 results and call for additional trend context . All S&P Global consensus data are marked with * and noted accordingly.